Category - Developments

Developments

Titan Pharmaceuticals implant for opioid use disorder attracts media attention in Canada

An implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) for the treatment of opioid use disorder (OUD) is drawing attention in Canada. Marketed under the brand name Probuphine, the first-of-its-kind implant delivers...

March 4, 2019

Developments

Genetic meta-analysis identifies four new genetic variants associated with Alzheimer’s disease

A genome-wide association study of 94,000 individuals has identified four new genetic variants that play a role in the development of late-onset Alzheimer’s disease (AD). Conducted by an international consortium of...

March 1, 2019

Developments

Novavax Phase 3 ResVax trial misses primary endpoint

Novavax (NASDAQ:NVAX) reported that its Phase 3 PREPARE studyfor ResVax, a RSV (respiratory syncytial virus) F vaccine, did not meet its primary objective of preventing medically significant RSV lower respiratory tract...

March 1, 2019

Developments

Guardant Health liquid biopsy beats tissue testing in advanced non-small cell lung cancer

In a prospective multi-center study of 282 newly diagnosed non-small cell lung cancer patients, Guardant Health’s (NASDAQ:GH) liquid biopsy genomic assay, Guardant360, outperformed standard-of-care tissue testing in...

March 1, 2019

Developments

BeyondSpring to report positive Plinabulin CIN data at ASCO-SITC

BeyondSpring (NASDAQ: BYSI) announced new clinical results from its Study 106 program for lead asset Plinabulin, which demonstrates that combining Plinabulin with Neulasta not only improves overall efficacy for...

February 26, 2019

Developments

Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine

Titan Pharmaceuticals (NASDAQ:TTNP) entered a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime to expand patient access to its Probuphine six-month implant for the maintenance...

February 25, 2019

Developments

Eyenovia posts positive results from second MicroStat Phase 3 trial

Eyenovia (NASDAQ:EYEN) reported positive results from its second Phase 3 study, MIST-2, evaluating the safety and efficacy of its MicroStat fixed-combination formulation for the treatment of pharmacologic mydriasis, or...

February 25, 2019

Developments

ImmunoPrecise Antibodies receives subcontract for rabbit monoclonal antibodies

ImmunoPrecise Antibodies (TSXV:IPA; OTC:IPATF) has received a five-year subcontract from Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the NCI, to discover and...

February 21, 2019

Developments

Clearlake Capital-backed symplr to acquire API Healthcare

symplr, a leading healthcare governance, risk and compliance (GRC) software-as-a-service (SaaS) platform, backed by Clearlake Capital Group, has agreed to acquire API Healthcare, a leading provider of healthcare human...

February 20, 2019

Developments

BioSig reports successful first-in-human use of PURE EP system

BioSig Technologies (NASDAQ:BSGM) reported that it successfully conducted first patient cases using its PURE EP system at the Texas Cardiac Arrhythmia Institute in Austin, Tex. PURE EP is an FDA-approved cardiac signal...

February 20, 2019

Category - Developments

Subscribe